Overall survival (OS): The arm in which Tevimbra was added to Ziihera and chemotherapy resulted in a statistically significant improvement in OS (median OS of 26.4 months) at IA1. The Ziihera plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results